Sarepta Therapeutics, Inc. (SRPT)

136,56 +2,66 (+1,99%) Alla chiusura: 04:00PM EDT

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 840

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Douglas S. Ingram Esq.	Pres, CEO & Director	1,55M	N/D	1963
Mr. Ian Michael Estepan	Exec. VP & CFO	861,75k	N/D	1976
Dr. Louise R. Rodino-Klapac Ph.D.	Exec. VP, Chief Scientific Officer and Head of R&D	929,68k	N/D	1978
Mr. Ryan E. Brown	Sr. VP, Gen. Counsel & Corp. Sec.	913,64k	N/D	1978
Bilal Arif	Sr. VP of Strategy and Operations & Chief Technical Operations Officer	N/D	N/D	N/D
Mary Jenkins	Sr. Mang. of Investor Relations	N/D	N/D	N/D
Ms. Alison Nasisi	Chief People Officer & VP	N/D	N/D	N/D
Dr. Diane L. Berry	Sr. VP of Global Health Policy and Gov. & Patient Affairs	N/D	N/D	N/D
Mr. Dallan Murray	Sr. VP & Chief Customer Officer	N/D	N/D	N/D
Mr. Joseph Bratica	Controller & VP	N/D	N/D	1964

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Sarepta Therapeutics, Inc. al 1 febbraio 2023 è 3. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 3; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.